Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 204-648-7 | CAS number: 123-75-1
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Link to relevant study record(s)
Description of key information
A toxicokinetic assessment was performed based on the available data of the substance. Furthermore, a publication (Hawksworth et al 1974) describing metabolism of piperidine is available. Data obtained with piperidine can be read across to pyrrolidine (rationale in Section 13).
Key value for chemical safety assessment
- Bioaccumulation potential:
- low bioaccumulation potential
- Absorption rate - oral (%):
- 100
- Absorption rate - dermal (%):
- 100
- Absorption rate - inhalation (%):
- 100
Additional information
Hawskworth et al (1974) describe that rats were orally dosed with 500µg piperidine. In 3/6 rats with urinary bladder infection approximately 0.2 µg nitrosopiperidine was found in the urine by GC-MS analysis, which represents a nitrosation of 0.04% of the amine dose. Similar results were obtained when pyrrolidine was used, but no exact data were given on this substance. A justification to read across data from piperidine to pyrrolidine is given in Section 13.
The low molecular weight (71.14) of pyrrolidine favours absorption in the gastro-intestinal tract by passive diffusion. The high water solubility (1000 mg/L) and the low log Pow (0.22) of pyrrolidine also favour absorption in the gastro-intestinal tract by passive diffusion.
Therefore, for risk assessment purposes, the oral absorption of pyrrolidine is set at 100% (1).
The results of the oral toxicity studies with pyrrolidine show severe corrosive effects after oral exposure to pyrrolidine, which may enhance uptake of the substance. These data do not provide reason to deviate from the proposed oral absorption percentage.
Pyrrolidine may be expected to be distributed widely throughout the body based on the small molecular weight. Based on the low lipophilicity and high water solubility of pyrrolidine bioaccumulation is expected to be low. Absorbed pyrrolidine might undergo biotransformation (3), of which the products are expected to be excreted via the urine as they are still low molecular weight compounds with high hydrophilicity.
The low molecular weight favours dermal absorption. Since the log Pow is low (0.22), pyrrolidine may be taken up in the stratum corneum to a limited extent, followed by transfer to the epidermis based on the high water solubility (1000 mg/L). According to the criteria given in the REACH guidance (1): 10% dermal absorption will be considered in case MW>500 and log Pow <-1 and >4, otherwise 100% dermal absorption should be chosen. The two available studies on acute dermal toxicity both report severe corrosive effects. Exposure to pyrrolidine will lead to disturbance of the dermal integrity which will enhance dermal absorption. Therefore, for risk assessment purposes, the dermal absorption of pyrrolidine is set at 100% (2).
The vapour pressure (64.5 hPa at 20 °C) indicates that pyrrolidine might be available for inhalation as a vapour. The high hydrophilicity (1000 mg/L) of pyrrolidine might prevent adsorption via the respiratory tract due to retention in the mucus. However, the moderate log Pow (0.22) allows absorption directly across the respiratory tract epithelium by passive diffusion. After inhalation exposure to pyrrolidine local effects were observed, caused by the corrosive properties of the substance. Taken together, 100% absorption via inhalation of pyrrolidine is proposed for risk assessment purposes.Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.